Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients

NDT Plus

Volumn 2, Issue 4, 2009, Pages 267-272

  Eddington, Helen ^a   Heaf, James G ^b  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

calcium; phosphate; PTH; uraemia; vitamin D

Indexed keywords

ALFACALCIDOL; ALUCAPS; ALUMINUM HYDROXIDE; CALCICHEW; CALCIDIOL 1 MONOOXYGENASE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE PLUS MAGNESIUM CARBONATE; CALCIUM CARBONATE; COLECALCIFEROL; ERGOCALCIFEROL; LANTHANUM CARBONATE; OSVAREN; PARACALCITOL; PARATHYROID HORMONE; PHOSEX PHOSLO; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ALUMINUM OVERLOAD; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE MINERAL; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE MINERAL BONE DISORDER; CONSTIPATION; DIALYSATE; DIET; DIET THERAPY; DISEASE COURSE; ELECTROLYTE DISTURBANCE; HEMODIALYSIS PATIENT; HORMONE METABOLISM; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; KIDNEY CALCIFICATION; KIDNEY DISEASE; NAUSEA; NEUROTOXICITY; NONHUMAN; PARATHYROIDECTOMY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; SOFT TISSUE CALCIFICATION; VASCULAR DISEASE; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

EID: 77955941116     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp044     Document Type: Review

References (54)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from KidneyDisease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
2. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906
3. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Arterial stiffness in renal patients: an update. Am J Kidney Dis 2005; 45: 965-977
4. Picton ML, Moore PR, Mawer EB et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000; 58: 1440-1449
5. Goodman WG, Ramirez JA, Belin TR et al.Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-1166
6. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. SeminDial 2004; 17: 209-216
7. Heaf JG. Causes and consequences of adynamic bone disease. Nephron 2001; 88: 97-106
8. Barreto FC,BarretoDV,MoysesRMet al.K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777
9. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
10. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38
11. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25- hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620
12. Saab G, Young DO, Gincherman Y et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-c138
13. Eknoyan G, Levin A, Levin NW. National Kidney Foundation: K/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S1-S201
14. Cuppari L, Carvalho AB, Draibe SA. Vitamin D status of chronic kidney disease patients living in a sunny country. J Ren Nutr 2008; 18: 408-414
15. van Direl M, Koedam M, Buurman CJ et al. Evidence for auto/paracrine actions of vitamin D in bone: 1-hydroxylase expression and activity in human bone cells. FASEB J 2006; 20: 2417-2419
16. Gallieni M, Kamimura A, Ahmed A et al. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 1995; 268: F746-F753
17. Holick MF. Vitamin D deficiency. New Eng J Med 2007; 357: 266-281
18. Dusso AS, Finch J, Brown A et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991; 72: 157-164
19. Lappe JM, Travers-Gustafson D, Davies KM et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586-1591
20. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013
21. Gonzalez EA, Sachdeva A, Oliver DA et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503-510
22. Zisman AL, Hristova M, Ho LT et al. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27: 36-43
23. Al-Aly Z, Qazi RA, Gonzaĺez EA et al. Changes in serum 25- hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50: 59-68
24. Chandra P,Binongo JN, ZieglerTRet al.Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008; 14: 10-17
25. Kooienga L, Fried L, Scragg R et al. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis 2009; 53: 408-416
26. Marsell R, Grundberg E, Krajisnik T et al. Fibroblast growth factor- 23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol 2008; 158: 125-129
27. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007; 194: 1-10
28. Gutierrez OM, MannstadtM, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
29. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
30. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
31. Schoppet M, Shroff RC, Hofbauer LC et al. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int 2008; 73: 384-390
32. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 54-66
33. Mathew S, Tustison KS, Sugatani T et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008; 19: 1092-1105
34. Ewence AE, Bootman M, Roderick HL et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008; 103: e28-e34
35. Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439
36. London GM, Blacher J, Pannier B et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38: 434-438
37. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
38. Qunibi W, Moustafa M, Muenz LR et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965
39. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441
40. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137
41. Mehrotra R, Martin KJ, Fishbane S et al. Higher strength lanthanum carbonate provides serumphosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol 2008; 3: 1437-1445
42. Persy VP, Behets GJ, Bervoets AR et al. Lanthanum: a safe phosphate binder. Semin Dial 2006; 19: 195-199
43. Hutchison AJ, Barnett ME, Krause R et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008; 110: c15-c23
44. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490
45. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing haemodialysis with paracalcitol or calcitriol therapy. New Eng J Med 2003; 349: 446-456
46. Brickman AS, Coburn JW, Friedman GR et al. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man. J Clin Invest 1976; 57: 1540-1547
47. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
48. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357
49. Tentori F, Hunt WC, Stidley CA et al.Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865
50. Shroff R, EgertonM, BridelMet al. A bimodal association of vitamin Dlevels and vascular disease in children on dialysis. J AmSoc Nephrol 2008; 19: 1239-1246
51. Chonchol M, Locatelli F, Abboud HE et al. A randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of Cinacalcet HCL in participants with CKD not receiving dialysis. Am J Kidney Dis 2009; 53: 197-207
52. Lopez I, guilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804
53. Costa-Hong V, Jorgetti V, Gowdak LH et al. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery 2007; 142: 699-703
54. Renal Association clinical practice guidelines, 4th edn, Module 2, complications, 2007. Available at: www.renal.org.uk/guidelines